Confidentiality agreements

Open discussions are key to any successful collaboration. To protect the rights of each partner, it is strongly advised to sign a confidentiality agreement before the discussions start. Then information can be exchanged freely to determine whether a formal collaboration is indeed possible and useful. If this is the case, the next step is to draw up a collaboration agreement.

Confidentiality agreements are also referred to as non-disclosure agreements (NDA) or confidential disclosure agreements (CDA).

CDA templates VU and VUmc

Standardized templates for Vrije Universiteit Amsterdam and VU University Medical Center can be found here.

These templates have been approved by IXA. If changes to the contents of the agreements are needed, IXA needs to be involved, otherwise just fill in the required fields and have the agreement signed by your department/faculty manager.

If you have questions regarding these templates, please contact:

Aniek Büller

Office Manager

a.buller@ixa.nl | 020-59 89 905

Ester Hulleman

Office Manager

e.hulleman@ixa.nl | 020-59 89 905

Start-up Cupplement receives investment in TV program Dragons Den

Is it possible to create a cup of coffee that’s healthy and tasty? At the entrepreneurship laboratory Demonstrator Lab at the Vrije Universiteit, Florian Fermin (27) and Stefan Wateler (26) developed Cuppelement, a Fairtrade biodegradable coffee capsule with added superfoods and vitamins. During the Dutch TV program Dragons Den, the entrepreneurs successfully persuaded the dragons […]

Optics11 and Optics11 Life secure funding to accelerate growth

Optics11 and Optics11 Life have secured funding from Rabobank. The funding will be used to strongly accelerate growth across global markets, to further build the team for the future and to strategically expand the high-tech product portfolios of both business units. “This is the right moment to pick up the pace. Rabobank’s funding helps us […]

Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorders

Azafaros B.V. announced today that the first cohort of healthy subjects has been dosed in a two-part Phase 1 clinical study with clinical candidate AZ-3102, a first-in-class small molecule compound being developed for the treatment of rare neurogenetic disorders. This double-blind, placebo-controlled, Phase 1 study is evaluating the safety and tolerability of ascending single- (SAD) […]